鶹ýӰ

Spotlight On

NSCLC

More in NSCLC

Does an Additional First-Line Option Alter Approach in EGFR-Mutant NSCLC?

The approval of lazertinib/amivantamab gives clinicians one more option

Nov 01, 2024
A computer rendering of lung cancer.
Taking on Acquired Resistance in EGFR-Mutant NSCLC

TKIs are the first-line of defense, but "the more options we have the better," expert says

Nov 01, 2024
A computer rendering of human cell membrane showing HER3 bound to an epidermal growth factor receptor molecule.

1.00 CME Credits
Improving Transitions of Care and Long-Term Outcomes for Patients With Spinal Muscular Atrophy (SMA)

0.50 CME Credits
Developing Patient-Centered Approaches to Optimize the Management of Bipolar I Disorder

2.00 CME Credits
Appropriate Healthcare Interventions in Elder, Child, and Intimate Partner Abuse

3.00 CME Credits
Pain Management and the 2022 CDC Guideline for Prescribing Opioids for Pain

1.00 CME Credits
Engaging Older Adults in Vaccine Education: A Toolkit for Healthcare Providers

0.50 CME Credits
Integrating Biomarkers and Guideline-Aligned Treatment Approaches Into Evidence-Based Care for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

1.00 CME Credits
Uncomplicated Urinary Tract Infections: Leveraging Real-World Insights to Improve Patient Care

0.25 CME Credits
Utilizing Biomarkers and Prognostic Factors to Identify Rheumatoid Arthritis Patients at Risk for Poor Outcomes